Replies to post #227488 on Biotech Values

[DewDiligence]

SNY-THOR merger PR:

https://www.globenewswire.com/news-release/2019/12/09/1957603/0/en/Sanofi-Sanofi-to-acquire-Synthorx-to-bolster-its-immuno-oncology-pipeline-for-2-5-Billion.html

…Under the terms of the merger agreement, Sanofi will commence a cash tender offer to acquire all of the outstanding shares of Synthorx common stock for $68 per share in cash for a total enterprise value of approximately $2.35 billion. The $68 per share acquisition price represents a 172% premium to Synthorx’s closing price on December 6, 2019.